Seeking Alpha

ImmunoCellular Therapeutics (IMUC) +19.3% premarket as Maxim Group begins coverage with a Buy...

ImmunoCellular Therapeutics (IMUC) +19.3% premarket as Maxim Group begins coverage with a Buy rating and an $18 price target. The firm says IMUC has the potential to create a new, innovative second-generation dendritic cancer vaccine to address perceived shortfalls of Dendreon's (DNDN) Provenge. If successful, the firm thinks it could become a billion-dollar product.
Comments (5)
  • perry48253
    , contributor
    Comments (5) | Send Message
     
    I invest in mostly biotech companies especially those that are easily overlooked by the big guys.
    6 Sep 2012, 09:57 AM Reply Like
  • perry48253
    , contributor
    Comments (5) | Send Message
     
    Doesn't NWBO have pretty much the same results but is already in a PH 3 Clinical trial?
    6 Sep 2012, 09:58 AM Reply Like
  • Hoang6
    , contributor
    Comments (345) | Send Message
     
    Market, market, market! Who did not hear IMUC was working on billion-dollar product before it took a nose-dive last month? Great move to cover loss big boys!
    6 Sep 2012, 10:50 AM Reply Like
  • paulwilliam
    , contributor
    Comments (6) | Send Message
     
    What I find scarey is that the exact same things were said of Dendreon a few years ago.
    6 Sep 2012, 11:29 AM Reply Like
  • jeffleppard
    , contributor
    Comment (1) | Send Message
     
    Dendreon killed me. I'm hoping IMUC can bring me back!!
    6 Sep 2012, 03:35 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs